SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
searching for the virus cure medical pills in pattern on vibrant background
FDA
Evolving FDA Accelerated Approval Pathway Suffers Spate of Withdrawals
As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining concerned about confirmatory trials and clinical efficacy, especially as products greenlit under this pathway are pulled from the market.
October 28, 2024
 · 
7 min read
 · 
Heather McKenzie
Opinion
New Therapies Are Set to Upend the Alpha-1 Antitrypsin Deficiency Treatment Space
Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could address the damage underlying alpha-1 antitrypsin deficiency and make today’s treatments a thing of the past.
October 28, 2024
 · 
3 min read
 · 
Jia Jie Chen
Courtesy of Sarepta Therapeutics
Duchenne muscular dystrophy
Sarepta’s Recent Elevidys Presentations Leave Duchenne Community Wanting
With Sarepta’s gene therapy Elevidys now available to a majority of Duchenne muscular dystrophy patients, experts express cautious optimism while emphasizing the need for further data.
October 28, 2024
 · 
6 min read
 · 
Heather McKenzie
Editorial
Analysts Rally Around Pfizer CEO Amid Starboard Challenge
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.
October 25, 2024
 · 
4 min read
 · 
Greg Slabodkin
Sanofi's Distribution Center in Quebec, Canada
Earnings
Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.
October 25, 2024
 · 
3 min read
 · 
Tristan Manalac
Exterior view of the headquarters of the Centers for Disease Control and Prevention in Atlanta, Georgia
Vaccines
CDC Reaffirm RSV Vaccination Guidelines, Declines Expanding Coverage to Younger Adults
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for adults aged 75 and older, and in seniors 60 to 74 years who are at risk of severe disease.
October 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: 3D concept art showing a bladder surrounded by cancer cells
Bladder cancer
Tyra Looks to Challenge J&J’s Balversa With Early Data for FGFR3 Blocker in Urothelial Carcinoma
Bank of America analysts said prior to Thursday’s readout that Tyra Biosciences’ TYRA-300 could rival Johnson & Johnson’s kinase inhibitor Balversa, which has suffered from safety concerns and poor tolerability.
October 25, 2024
 · 
3 min read
 · 
Tristan Manalac
2D illustration showing scientists' hands editing a DNA strand
Rare diseases
Intellia’s CRISPR Gene Editor Cuts Hereditary Angioedema Attacks by 81% in Phase II Study
Jefferies analyst Maury Raycroft said in a note to investors that Thursday’s mid-stage readout pointed to the “unprecedented” complete response rate of Intellia’s investigational in vivo gene editing therapy in the disorder.
October 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Watercolor illuatration on white background creative mind
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
 · 
2 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS